NDAINJECTIONINJECTABLE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
INTRALIPID 30% (i. v. fat emulsion) by Fresenius Kabi is clinical pharmacology intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. First approved in 1993.
Drug data last refreshed 9h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTRALIPID 30% is an intravenous fat emulsion that serves as a parenteral nutrition source for patients requiring total parenteral nutrition (TPN) support. It provides essential fatty acids and calories, preventing and correcting essential fatty acid deficiency (EFAD) while being metabolized as an energy substrate with increased heat production and oxygen consumption.
LOE Approaching
As LOE approaches with moderate competitive pressure (30%), brand team focus will shift from market share defense to cost optimization and customer retention strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the…
Pharmacologic Class:
Lipid Emulsion
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INTRALIPID 30% offers exposure to hospital-based commercial operations, healthcare economics, and parenteral nutrition specialty markets. Career development focuses on defensive strategies, cost management, and relationship-building with critical care and nutrition support teams rather than launch-phase innovation.
Product Manager
Worked on INTRALIPID 30% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.